"10.1371_journal.ppat.1002142","plos pathogens","2011-07-28T00:00:00Z","Kenneth Plante; Eryu Wang; Charalambos D Partidos; James Weger; Rodion Gorchakov; Konstantin Tsetsarkin; Erin M Borland; Ann M Powers; Robert Seymour; Dan T Stinchcomb; Jorge E Osorio; Ilya Frolov; Scott C Weaver","Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America; Inviragen Inc, Madison, Wisconsin and Fort Collins, Colorado, United States of America; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, United States of America; Division of Vector Borne Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, United States of America; Department of Microbiology, University of Alabama, Birmingham, Alabama, United States of America","Conceived and designed the experiments: KP EW CDP RS DS JO IF SCW. Performed the experiments: KP EW CDP RG KT EMB AMP RS JW. Analyzed the data: KP EW CDP RG KT EMB AMP RS. Wrote the paper: KP RS SCW.","CDP, JW and DTS are employees of Inviragen, Inc. DTS is a stockholder and board member of Inviragen, Inc. JEO is a consultant and stockholder of Inviragen, Inc. IF and SCW are inventors on a UTMB patent application describing IRES-attenuated alphavirus vaccines. Inviragen has obtained license to the patent for commercial development.","2011","07","Kenneth Plante","KP",13,TRUE,8,9,8,3,TRUE,TRUE,FALSE,0,NA,FALSE
